The global artificial heart-lung machine market reached a value of US$ 319.3 Million in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries. These insights are included in the report as a major market contributor.
An artificial heart-lung machine, also known as a cardiopulmonary bypass (CPB) or oxygenator pump, is used during coronary artery bypass, heart and lung transplants, and other cardiac surgeries. It temporarily performs the functions of the heart and lungs to enable the surgeon to operate in motion and bloodless surgical field. These machines consist of a chamber that receives blood, which is then oxygenated and circulated to all body parts. Over the years, these pumps have helped in making significant advances in the management of severe respiratory failure as well as in the field of car-diac surgeries.
In recent years, there has been a significant rise in the number of open-heart surgeries, heart transplants and lung surgeries across the globe. This can primarily be attributed to various environmental and lifestyle changes, which have led to an increase in the prevalence of cardiovascular diseases and the instances of organ failures. Other than this, governments of several developing nations are making efforts for providing improved healthcare facilities to patients, which is driving the demand for artificial heart-lung machines. Furthermore, the market players are investing in research and development activities to modernize the current models of oxygenator pumps. These activities have led to the development of modular heart-lung machines that are cost-effective, safe, and user-friendly in nature. Besides this, these machines also offer flexibility to doctors as they are portable and can be operated on rechargeable batteries. The manufacturers have also made several improvements in CPB pumps to prevent the over-oxygenation of blood.
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic Inc, Sorin Group, MAQUET GmbH & Co. KG, Terumo Corporation, C.R. Bard Inc, Tianjin Medical, Edwards Lifesciences, Jarvik Heart, Braile Biomédica, SynCardia, etc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at